Seminars in Nephrology
Volume 28, Issue 3 , Pages 289-296 , May 2008

Vasopressin and Aquaporin 2 in Clinical Disorders of Water Homeostasis

  • Robert W. Schrier, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert W. Schrier, Division of Renal Diseases and Hypertension—School of Medicine, Department of Medicine, University of Colorado at Denver Health Sciences Center, 4200 E Ninth Ave, Box B173, Denver, CO 80262-3706.

References 

  1. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature. 1992;357:333–335
  2. Sands J, Bichet D. Nephrogenic diabetes insipidus. Ann Intern Med. 2006;144:186–194
  3. Wade JB, Stetson DL, Lewis SA. ADH action: evidence for a membrane shuttle mechanism. Ann N Y Acad Sci. 1981;372:106–117
  4. Agre P, Preston GM, Smith BL, Jung JS, Raina S, Moon C, et al. Aquaporin CHIP the archetypal molecular water channel. Am J Physiol Renal Fluid Electrolyte Physiol. 1993;265:F463–F476
  5. Fushimi K, Uchida S, Hara K, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature. 1993;361:549–552
  6. Nielsen S, Frokiaer J, Marples D, Kwon T-H, Agre P, Knepper M. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205–244
  7. Bichet DG. Lithium, cyclic AMP signaling, A-kinase anchoring proteins, and aquaporin-2. J Am Soc Nephrol. 2006;17:920–922
  8. DiGiovanni S, Nielsen S, Christensen E, Knepper M. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rats. Proc Natl Acad Sci U S A. 1994;91:8984–8988
  9. Wade J, Nielsen S, Coleman R, Knepper M. Long-term regulation of collecting duct water permeability: freeze-fracture analysis of isolated perfused tubules. Am J Physiol Renal Fluid Electrolyte Physiol. 1994;166:F723–F730
  10. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992;105:787–791
  11. Schrier RW. The sea within us: disorders of body water homeostasis. Curr Opin Invest Drugs. 2007;8:304–311
  12. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21:70–76
  13. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol. 2006;17:1820–1832
  14. Lee W, Packer M. Prognostic importance of serum concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–267
  15. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
  16. Szatalowicz V, Arnold P, Chaimovitz C, Bichet D, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med. 1981;305:263–266
  17. Xu D, Martin P-Y, Ohara M, St. John J, Pattison T, Meng X, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure. J Clin Invest. 1997;99:1500–1505
  18. Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, Jonassen T, et al. Congestive heart failure in rats in associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci U S A. 1997;94:5450–5455
  19. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–1971
  20. Abraham WT, Shamshirsaz AA, McFann K, Orem RM, Schrier RW. Aquaretic effect of lixivaptan, an oral non-peptide, selective V2 receptor vasopressin antagonist, in the New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006;47:1615–1621
  21. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. SALT Investigators Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  22. Saito T, Ishikawa SE, Sasaki S, Nakamura T, Rokkuka K, Kawakami A, et al. Urinary excretion of aquaporin-2 in the diagnosis of central diabetes insipidus. J Clin Endocrinol Metab. 1997;82:1823–1827
  23. Martin PY, Abraham WT, Xu L, Olson BR, Oren RM, Ohara M, et al. Selective V2 receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol. 1999;10:2165–2170
  24. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials). JAMA. 2007;297:1332–1343
  25. Konstam M, Gheorghiade M, Burnett J, Grinfeld L, Maggioni A, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007;297:1319–1331
  26. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990;113:155–159
  27. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henricksen J, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157
  28. Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? (Editorial). J Am Soc Nephrol. 2007;18:2028–2031
  29. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236
  30. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med. 1982;96:413–417
  31. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther. 1998;63:561–570
  32. Ivarsen P, Frokiaer J, Aagaard N, Hansen E, Bendtsen F, Nielsen S, et al. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut. 2003;52:1194–1199
  33. Gerbes AL, Gulerg V, Gines P, Decauz G, Gross P, Gandjini H, et al. VPA Study Group Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939
  34. Briner V, Cadnapaphornchai M, Schrier RW. Hypertension and pregnancy. In:  Schrier RW editors. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2007;p. 1326–1350
  35. Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int. 1998;54:2056–2063
  36. Schrier RW, Briner VA. Peripheral arterial vasodilation hypothesis of sodium and water retention in pregnancy: implications for pathogenesis of preeclampsia-eclampsia state. Obstet Gynecol. 1991;77:632–639
  37. Ohara M, Martin P-Y, Xu D-L, St. John J, Pattison T, Kim J, et al. Upregulation of aquaporin 2 water channel expression in pregnant rats. J Clin Invest. 1998;101:1076–1083
  38. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med. 1998;33:533–541
  39. Cadnapaphornchai MA, Ohara M, Morris KG, Knotek M, Rogachev B, Ladtkow T, et al. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. Am J Physiol Renal Physiol. 2001;280:F592–F598
  40. Potter RR. Water retention due to oxytocin. Obstet Gynecol. 1964;23:699–702
  41. Lyness J, Robinson AG, Sheridan MN, Gash DM. Antidiuretic effects of oxytocin in the Brattleboro rat. Experientia. 1985;41:1444–1446
  42. Li C, Wang W, Summer S, Westfall T, Brooks D, Falk S, et al. Effect of oxytocin on water channel expression and trafficking in Brattleboro rats: role of V2 receptor. J Am Soc Nephrol. 2008;19:225–232
  43. Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med. 1978;64:613–621
  44. Chen Y-C, Cadnapaphornchai MA, Yang J, Summer S, Falk S, Li C, et al. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am J Physiol Renal Physiol. 2005;289:F672–F678
  45. Chen Y-C, Cadnapaphornchai MA, Summer S, Falk S, Li C, Wang W, et al. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol. 2005;16:2864–2871
  46. Evered DC, Hayter CJ, Surveyor I. Primary polydipsia in thyrotoxicosis. Metabolism. 1972;21:393–404
  47. Wang W, Li C, Summer SN, Falk S, Schrier RW. Polyuria of thyrotoxicosis: Downregulation of aquaporin water channels and increased solute excretion. Kidney Int. 2007;72:1088–1094
  48. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate 1. N Engl J Med. 1971;285:1231–1243
  49. Klein JD, Murrell BP, Tucker S, et al. Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension. Am J Physiol Renal Physiol. 2006;291:F952–F959
  50. Ishikawa S, Schrier RW. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int. 1982;22:587–593
  51. Ufferman RC, Schrier RW. Importance of sodium intake and mineralocorticoid hormone in the impaired water excretion in adrenal insufficiency. J Clin Invest. 1972;57:1639–1646
  52. Ohara M, Cadnapaphornchai MA, Summer S, Falk S, Yang J, Togawa T, et al. Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat. Biochem Biophy Res Commun. 2002;299:285–290
  53. Chen Y-C, Cadnapaphornchai MA, Summer S, Falk S, Li C, Wang W, et al. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol. 2005;16:2864–2871
  54. Agus Z, Goldberg M. Role of antidiuretic hormone in the abnormal water diuresis of anterior hypopituitarism in man. J Clin Invest. 1971;50:1478–1489
  55. Kim J, Summer S, Wood W, Schrier RW. Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun. 2001;289:1252–1256
  56. Wang W, Li C, Summer S, Falk S, Cadnapaphornchai MA, Chen Y-C, et al. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am J Physiol Renal Physiol. 2006;290:F1135–F1142

PII: S0270-9295(08)00052-1

doi: 10.1016/j.semnephrol.2008.03.009

Seminars in Nephrology
Volume 28, Issue 3 , Pages 289-296 , May 2008

Article Tools

* Image Usage & Resolution